Indaptus Therapeutics (INDP) said Friday it sold about $2.3 million of convertible promissory notes and accompanying warrants in a private placement.
A health care-focused institutional investor led the transaction in an ongoing offering, in which Indaptus is looking to raise gross proceeds of up to $5 million, the company said.
Indaptus said the notes bear an annual interest rate of 6%, will mature on July 28, 2026 and will convert into common shares, while the warrants to purchase 200% of the conversion shares will be issued after the conversion of the notes and the receipt of stockholder approval.
The company said it plans to use the net proceeds for research and development, including a phase 1b/2 clinical trial, and for working capital and general corporate purposes.
Indaptus shares were 2.7% lower in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。